MDX Medx Health Corp

MISSISSAUGA, ON, Aug. 22, 2012 /CNW/ - MedX Health Corp., (TSXV.MDX) a global leader in drug free, non-invasive low level laser light therapy for tissue repair and pain relief today reported their revenues of $158,042 for the second quarter ended June 30, 2012, representing a 10% decline from revenues of $174,951 for the quarter ended June 30, 2011. The loss for the second quarter of 2012 was $364,904 or $0.01 per share compared to a loss of $185,290 or $0.01 per share for the second quarter of 2011. About MedX Health Corp. MedX is a twelve (12) year old Canadian company, headquartered in Mississauga, Ontario (Toronto), and is a global leader in the design, manufacturing and distribution of quality low level laser and light therapy technologies for use in numerous medical settings, including rehab/chiropractic, dental, wound care, and veterinary medicine, providing patients with drug free and non-invasive treatment of tissue damage and pain. MedX laser and light products are FDA approved, Health Canada cleared, and CE Mark approved for use in North America as well as the European Union.  MedX Health acquired the worldwide assets of MoleMate in June, 2011.  For a complete profile of MedX Health Corp. and its products visit www.medxhealth.com. About MoleMate Imaging and Skin Cancer MoleMate recently received approval from Health Canada, and is immediately available and in stock for all Canadian physicians, joining their colleagues in Europe, the UK, Australia, and the US, who have been utilizing this new pain-free, non-invasive imaging system to 'See More', approximately 2mm below the surface of suspicious moles, and provide additional information and images related to every mole and all types of melanomas and non-melanomas. MoleMate uses a patented device and technology that features a hand-held scanner designed for office use that utilizes light to view beneath suspicious moles or lesions in a pain free, non-invasive manner, creating images for physicians to evaluate all types of moles and lesions within seconds, providing images that can reveal if a mole is benign, or something more serious, often eliminating the need for skin biopsies, resulting in less pain, scarring, and expense.  Physicians interested in learning more should contact MedX Health Corp. at www.simsys-molemate.com. This press release does not constitute an offer of any securities for sale.  This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation.  These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements.  All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. MedX Health Corp. CONTACT: Investors:Steve Guillen / President and Chief Executive OfficerMedX Health Corp. investor@medxhealth.comPhone: (905) 670-4428

Copyright